Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
| Status: | Archived |
|---|---|
| Conditions: | Cancer, Blood Cancer, Lymphoma, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | July 2009 |
A Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients With Lymphoma
RATIONALE: Panobinostat and everolimus may stop the growth of cancer cells by blocking some
of the enzymes needed for cell growth and by blocking blood flow to the cancer. Giving
panobinostat together with everolimus may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of panobinostat when
given together with everolimus in treating patients with relapsed or refractory lymphoma or
multiple myeloma.
OBJECTIVES:
Primary
- To evaluate the safety and feasibility of combining panobinostat with everolimus in
patients with recurrent or refractory lymphoma or multiple myeloma.
- To define the maximum tolerated dose of panobinostat in combination with everolimus in
these patients.
Secondary
- To obtain preliminary data for response to this treatment regimen in these patients.
- To perform correlative studies relevant to this treatment regimen.
OUTLINE: This is a dose-escalation study of panobinostat.
Patients receive oral panobinostat 3 days a week and oral everolimus once every other day
for 4 weeks Courses repeat every 4 weeks in the absence of disease progression or
unacceptable toxicity.
Blood and bone marrow samples may be collected for pharmacokinetic and correlative
laboratory studies.
After completion of study treatment, patients are followed up for ≥ 4 weeks.
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials